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ABSTRACT 
Isolated Regional Perfusion for Metastases of Malignant 
Melanoma - Clinical and Experimental studies 
Roger Olofsson 
Department of Surgery, Institute of Clinical Sciences at 
Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden 
Background Isolated regional perfusion is a treatment option mainly for localized 
metastatic disease. The principle idea is to surgically isolate a region of the body and 
connect the circulation to a heart-lung machine. A high concentration of a 
chemotherapeutic agent is then delivered to the tumour, while systemic toxicity is 
avoided. The aim of this thesis was to evaluate clinical outcome of isolated regional 
perfusion for extremity and liver metastases of malignant melanoma, investigate 
associated immunological mechanisms, and to explore the potential use of tumour-
derived exosomes as future biomarkers. 
Methods Clinical outcome was analysed by retrospective studies of patient medical 
records and by data from the national patient registers. Tumour specific T-cells were 
studied by flow cytometry analyses before and after perfusion. Exosomes were 
isolated from liver perfusate by ultra-centrifugation and thereafter characterized by 
electron microscopy, flow cytometry and real-time PCR of the RNA content.  
Results Between 1984 and 2008, 163 patients with melanoma in-transit metastases 
underwent isolated limb perfusion (ILP). The overall response rate was 85%, with 
65% of the patients having a complete response. Local progression occurred in 63% 
of the patients after a median time of 16 months. Predictive factors for response were 
mainly attributed to tumour burden. Thirty-four patients, with uveal melanoma liver 
metastases, underwent isolated hepatic perfusion (IHP). The overall response rate 
was 68%. There was a significant median overall survival advantage of 14 months 
(p=0.029) compared with the longest surviving patients in Sweden during the same 
time period. Immunological factors were studied in twelve patients after ILP, and the 
results showed a significant elevation of Melan-A+ CD8+ T-cells after four weeks in 
30% of the patients.  Exosomes were isolated from the liver perfusate and were 
shown to be Melan-A positive with a miRNA profile associated with melanoma. 
Conclusion ILP is a surgical method with a high response rate for the palliative 
treatment of patients with in-transit metastases of melanoma. IHP is a treatment 
option with a high response rate, and with a potential survival benefit of more than 
one year. A small increase in Melan-A specific T-cells is induced after ILP, however 
the clinical significance needs to be further assessed. Tumour-derived exosomes can 
be isolated from liver perfusate during IHP. The miRNA characteristics of these 
exosomes could be a potential source for future biomarkers. 
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